OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/RET
Lung Cancer — Non-Small Cell (NSCLC)RET Clinical Trials
RET fusions — most commonly KIF5B-RET and CCDC6-RET — drive 1–2% of NSCLC. Selpercatinib and pralsetinib are FDA-approved selective RET inhibitors with high response rates and intracranial activity. Trials investigate resistance mechanisms, combination strategies, and activity in RET-amplified or RET point-mutant disease.
Top recruiting RET Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count. See all 22 trials matched to your profile →
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NovoCure GmbH
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Shouyao Holdings (Beijing) Co. LTD
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Sinocelltech Ltd.
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network